It really wasn't that long ago when rampant enthusiasm for minimally invasive heart valves sent the shares of Edwards Lifesciences
rocketing from around $22 to almost $110 per share in about four and a
half years. While the stock was in the $90s, I dutifully played my role
of Cassandra -- pointing out that analysts and investors were getting
carried away with their expectations for the adoption of transcatheter
heart valves and underestimating the risks of competition from companies
like Medtronic (NYSE: MDT ) .
Please read the full article here:
http://www.fool.com/investing/general/2013/09/30/the-expectations-hangover-still-hurting-edwards-li.aspx
No comments:
Post a Comment